Yunhong Tian

Dr. Yunhong Tian

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YTYunhong Tian
Yunhong Tian
JWJianlin Wu
Jianlin Wu
CCCristian Chagas
Cristian Chagas
YDYichao Du
Yichao Du
HLHuan Lyu
Huan Lyu
JHJiani Hu
Jiani Hu
Accurate and early prognosis of disease is essential to clinical decision making, particularly in diseases, such as HCC, that are typically diagnosed at a late stage in the course of disease and therefore carry a poor prognosis. CDCA5 is a cell cycle regulatory protein that has shown prognostic value in several cancers. We retrospectively evaluated 178 patients with HCC treated with curative liver resection between September 2009 and September 2012 at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients were screened for their CDCA5 expression levels and assigned to either the high or low expression group. Patient demographics, comorbidities, clinicopathologic data, such as tumor microvascular invasion status and size, and long-term outcomes were compared between the two groups. The effect of CDCA5 on the proliferation of liver cancer cells was analyzed using in vitro and in vivo assays. The present study found that increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC. It was also found that CDCA5 overexpression may be associated with liver cancer cells. Additionally, this study confirmed that CDCA5 expression was increased in HCC tissue versus normal liver tissue, that CDCA5 expression was associated with decreased survival and that CDCA5 knockdown using shRNA led to cell cycle arrest in the G2/M phase. These findings suggest that CDCA5 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

29 May 2023 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
LMLongyin Ma
Longyin Ma
HLHeng Luo
Heng Luo
SKShien Kou
Shien Kou
ZGZhenguo Gao
Zhenguo Gao
DBDan Bai
Dan Bai
YTYunhong Tian
Yunhong Tian

30 July 2024 in BMC Surgery
Verified
Journal Article
Open access
PDF file
YLYu Lei
Yu Lei
XLXiyan Lei
Xiyan Lei
GCGuobiao Chen
Guobiao Chen
ZWZhenhong Wang
Zhenhong Wang
HSHonghua Song
Honghua Song
YTYunhong Tian
Yunhong Tian
Laparoscopic Sleeve Gastrectomy (LSG) and Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) are the two most commonly performed bariatric surgeries for the treatment of obesity. This meta-analysis was performed with the aim of summarizing the available evidence on weight loss, remission of comorbidities, and quality of life in LRYGB and LSG, complementing the current literature. We searched PubMed, EMBASE and the Cochrane Library from January 2012 to June 2023 for randomized controlled trials and non-randomized interventional studies. We finally selected 18 eligible studies. LRYGB resulted in greater weight loss compared with LSG at 5 years [WMD= -7.65 kg/m², 95% confidence interval (CI) -11.54 to -3.76, P = 0.0001], but there exists high heterogeneity with I²=84%. Resolution rate of type 2 diabetes mellitus (T2D) (OR = 0.60, 95%Cl 0.41–0.87, p = 0.007) and dyslipidemia (OR = 0.44, 95%Cl 0.23–0.84, p = 0.01) was higher in the LRYGB group than that in the LSG group at 5 years. There was no difference between LRYGB and LSG for remission of hypertension, and obstructive sleep apnea. No differences were observed in the QoL after LRYGB or LSG. Morbidity was lower in the LSG group (WMD = -0.07, 95% CI: -0.13, -0.02, P = 0.01) than in the LRYGB group. No statistically significant difference was found in mortality between the two procedures. At 5 years after surgery, LRYGB resulted in greater weight loss and achieved better remission rate of T2D and dyslipidemia than LSG. However, LSG has a lower morbidity rate than that of LRYGB.

25 July 2022 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JHJiarong Huang
Jiarong Huang
JSJinxuan Song
Jinxuan Song
XLXiangyu Li
Xiangyu Li
SLShuangfei Liu
Shuangfei Liu
WHWentao Huang
Wentao Huang
JHJiani Hu
Jiani Hu
Background: Studies have shown that long noncoding RNAs and N6-methyladenosine play important roles in gastric cancer. The purpose of this study was to determine the correlation and prognostic value of m6A-related lncRNAs and immune infiltration in gastric cancer. Methods: We downloaded the clinically related information and RNA-Seq transcriptome data of gastric cancer patients from the TCGA database. Univariate Cox regression analysis and Pearson analysis were used to screen out m6A-related lncRNAs. Consensus cluster analysis was used to divide the sample into two clusters, and LASSO analysis and Cox regression analysis were used to construct a risk scoring model. Results: A total of 25 lncRNA expression profiles were screened, and gastric cancer patients were divided into different subtypes. Cluster 2 had a better prognosis, but its stromal score, ESTIMATE score and immune score were low. Cluster 1 was rich in resting memory CD4 T cells, regulatory T cells, monocytes, and resting mast cells, and Cluster 2 was rich in activated memory CD4 T cells and follicular helper T cells. Thirteen lncRNAs were selected to construct a risk model, and the prognosis of gastric cancer patients in the high-risk group was poor. The expression of PD-L1 in tumours is significantly higher than that in normal tissues. Univariate and multivariate Cox regression analysis results showed that the overall survival rate was significantly related to stage and the risk score, which can be used as an independent prognostic factor. The results of the heatmap and scatter plot showed that clusters (P = 0.0045) and grade (G1–2, G3, P = 0.0037) were significantly related to prognosis. The relationship between the risk score and immune cell infiltration showed that memory B cells, resting dendritic cells, M0 macrophages, and M2 macrophages were positively correlated with the risk score, while resting mast cells, monocytes, activated NK cells, and follicular helper T cells were negatively correlated with the risk score. Conclusion: The results of this study indicate that m6A-related lncRNAs may play an important role in the prognosis of gastric cancer patients and the tumour immune microenvironment and may provide help for the treatment of gastric cancer patients.

20 November 2023 in International Journal of Surgery
Verified
Journal Article
Open access
LMLongyin Ma
Longyin Ma
ZGZhenguo Gao
Zhenguo Gao
HLheng luo
heng luo
SKShien Kou
Shien Kou
YLYu Lei
Yu Lei
YTYunhong Tian
Yunhong Tian
Objective: Postoperative staple line leakage (SLL) after sleeve gastrectomy (SG) is a rare but serious complication. Many surgeons routinely test anastomosis with an intraoperative leak test (IOLT) as part of the SG procedure. This meta-analysis aims to determine whether an IOLT plays a role in reducing the rate of postoperative staple line related complications in patients who underwent SG. Methods: The authors searched the PubMed, Web of science, the Cochrane Library, and Clinical Trials.gov databases for clinical studies assessing the application of IOLT in SG. The primary endpoint was the development of postoperative SLL. Secondary endpoints included the postoperative bleeding, 30 days mortality rates, and 30 days readmission rates. Results: Six studies totaling 469 588 patients met the inclusion criteria. Our review found that the SLL rate was 0.38% (1221/ 324 264) in the IOLT group and 0.31% (453/ 145 324) in the no intraoperative leak test (NIOLT) group. Postoperative SLL decreased in the NIOLT group compared with the IOLT group (OR=1.27; 95% CI: 1.14–1.42, P=0.000). Postoperative bleeding was fewer in the IOLT group than that in the NIOLT group (OR 0.79; 95% CI: 0.72–0.87, P=0.000). There was no significant difference between the IOLT group and the NIOLT group regarding 30 days mortality rates and 30 days readmission rates (P>0.05). Conclusion: IOLT was correlated with an increase in SLL when included as a part of the SG procedure. However, IOLT was associated with a lower rate of postoperative bleeding. Thus, IOLT should be considered in SG in the situation of suspected postoperative bleeding.

3 June 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
HLHeng Luo
Heng Luo
ZGZhenguo Gao
Zhenguo Gao
XLXiyan Lei
Xiyan Lei
JZJian Zhou
Jian Zhou
ZWZhenhong Wang
Zhenhong Wang
YTYunhong Tian
Yunhong Tian
This systematic review and meta-analysis aimed to evaluate the effectiveness of endoscopic vacuum therapy (EVT) compared with standard care in managing colorectal anastomotic leakage, a serious complication following colorectal surgery. We conducted a literature search across PubMed, Embase, and the Cochrane Library for clinical studies published before October 2024 that compared the outcomes of EVT and standard care for anastomotic leakage, including leakage resolution rates, treatment duration, hospital stay duration, or postoperative complications. The pooled estimates of risk ratio (RR) or mean difference were primarily derived using a fixed-effects model, with a random-effects model used when high heterogeneity was detected. The analysis included six observational studies (273 patients). EVT was associated with a significantly higher resolution rate compared with standard care (RR 1.18, 95%CI 1.03 to 1.35; P = 0.02). Treatment duration was significantly shorter in the EVT group (mean difference −30.6 days, 95%CI −43.5 to −17.7; P < 0.001), while hospital stay duration showed no significant difference between EVT and standard care (mean difference 1.7 days, 95%CI −4.2 to 7.7; P = 0.57). No statistically significant difference was found in the rate of treatment-related complications between EVT and standard care (RR 1.17, 95%CI 0.52 to 2.80; P = 0.71). This meta-analysis suggests that EVT has superior effectiveness in terms of leakage resolution rates, as well as a shorter treatment duration compared with standard care for colorectal anastomotic leakage. This study is however constrained by the lack of prospective data, the risk of selection bias, and heterogeneity, requiring cautious interpretation of the findings. PROSPERO registration: CRD 4873455814.